About the Biologics Innovation Facility
In this current climate, it’s really important that we have universities and industry collaborating
really closely on research and development projects.
GMP Lite is about what we can do in biomaufacturing in general – how we can use life to create
new products in different kinds of ways, whether it’s through mammalian cell cultures or
through many other algae cells and so on.
I think the other dimension that’s really important about GMP Lite is the engagement
between academia and industry – that is, it’s a facility which is not just about
university research and university training; it’s about engaging with industry and engaging
in training industry and using that facility to prototype, to explore, to start to develop
new products that industry are genuinely engaged in.
I think GMP in Australia is the first of its kind.
It is equipped with single-use manufacturing tools, which is kind of like a green way of
manufacturing going forward, using much less water, much less chemicals, having a much
lesser carbon footprint compared to the traditional stainless-steel manufacturing system.
When we talk to industry and government representatives, it becomes clear that we really do have a
talent gap, a lack of expertise, in that area of the biotech industry and facilities such
as the GMP will actually provide a means for us to provide that training.
So in addition to offering education and training to the biologics workforce of the future,
the GMP Lite facility also is potentially a sandbox for development of processes.
The value of a sandbox approach is that processes for production can be trialled and refined
before proceeding to a risky and expensive production run.
A GMP facility actually gives us focused R&D in this area and how we might be able to scale
up our manufacturing processes here in Australia and then transfer them to our larger biologic
I think we have been a little bit behind the rest of the world in terms of competitiveness.
Clinical trials are really that big next step, and good clinical trials.
Getting that actual last piece of the puzzle that says, ‘yes, we can now help you to
make your product at the quality you need locally’ is a big step forward.
So, the biotech space in Australia in 10 years’ time will hopefully be vibrant and will have
expanded a lot from where it is today, hopefully is broader in terms of the type of drugs that
are being made and developed and hopefully commercialised and that there’s more of
an end-to-end business in Australia for biotech.
The opportunity for Australia and the impact this can have on Australia and the competitiveness
in really the growth industry of the world, which is Southeast Asia, is here, and there
really is an opportunity to capture that enormous growth across biologics manufacturing and
the next generation of human therapeutic manufacturing.
So, really, this is the time, this is now, and I think Australia, and New South Wales
in particular, in investing in this, is at the cusp to be able to create our own destiny.
Global teaching partner with NIBRT
The NSW node of National Biologics Facility
Supported by NSW and NCRIS
Single-use platform technology by GE Healthcare
News and Events
New funding for biologics facility will keep research local
GlyTherix Ltd has announced that a consortium led by the company are the successful recipients of a competitive grant in Round 9 of the Federal Government’s Cooperative Research Centres Projects.